FATE THERAPEUTICS INC (FATE) Stock News

USA - NASDAQ:FATE - US31189P1021 - Common Stock

1.635 USD

+0.02 (+1.55%)

Last: 10/10/2025, 9:24:01 PM

1.5912 USD

-0.04 (-2.68%)

After Hours: 10/10/2025, 9:24:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

FATE Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

8 days ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

10 days ago - By: Benzinga - Mentions: NBY APDN GOVX SCYX ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

a month ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Benzinga

4 Analysts Assess Fate Therapeutics: What You Need To Know

a month ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Upcoming Investor Conferences

2 months ago - By: Zacks Investment Research - Mentions: RNA

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

2 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

2 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

2 months ago - By: Zacks Investment Research - Mentions: ENTA

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: HCAT

Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates

2 months ago - By: Zacks Investment Research - Mentions: VRDN

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

2 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

4 months ago - By: Fate Therapeutics, Inc. - Mentions: NBIX

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

5 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

5 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

5 months ago - By: Zacks Investment Research - Mentions: HALO ALLO

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus

5 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

5 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

5 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

5 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

6 months ago - By: Stocktwits - Mentions: VTI IWM

Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic

6 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

6 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

6 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)